HYBRID EVENT: You can participate in person at Orlando, USA or Virtually from your home or work.

6th Edition of International Conference on Neurology and Brain Disorders

October 24 -26, 2022

October 24 -26, 2022 | Orlando, Florida, USA
INBC 2022

Sachin Kumar

Speaker at Neurology and Brain Disorders 2022 - Sachin Kumar
Western Sydney University, Australia
Title : Nanocarrier Based Brain Delivery of Camelid Derived Antibodies For The Treatment Of Alzheimer's Disease


Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, clinically characterised by progressive impairment of memory, cognitive ability, and behavioural changes. As per World Health Organisation statistics 55 million people are currently living with dementia. AD being the biggest contributor to dementia with up to 70% of the total dementia cases. Microscopically, AD is characterised by deposition of extracellular senile plaques caused by β-amyloid accumulation and intracellular neurofibrillary tangles caused by abnormal hyper-phosphorylation of tau protein. Other macroscopic lesions also include cortical atrophy and ventricular enlargement. To date, drug delivery to the central nervous system for the therapeutic advancement of AD poses a unique challenge, as the blood brain barrier (BBB) is very selective and tightly control the influx of therapeutic compounds. Previously, we have demonstrated that our proprietary novel single domain antibodies are capable to cross the BBB via receptor-mediated transcytosis and displayed high binding affinity for Aβ peptides and phosphorylated Tau and reverse the signs associated with AD in mice. However, significant quantity of the antibodies is found in peripheral organs post intraperitoneal administration. Therefore, we developed a chitosan based nano carrier system, exploiting its unique properties such as ultra-low toxicity and capability of surface modification for encapsulation and surface coating will lead to enhanced transport of larger quantities of our novel single domain antibodies to treat AD. In this study we were able to fabricate and stage wise optimise and characterise the chitosan nano-carriers with reproducible size range of ~1000 nm, 35±5 mV zeta potential and successfully encapsulate and coat them with our proprietary antibodies,  we tested the effect of body biological fluids on nanoparticle formulations and currently running studies in-vitro evaluation of nano carrier systems various cell culture models are used for assessing therapeutic effects, cross migration and toxicity. 

What will audience learn from your presentation?

  • My presentation would spread light on the brain delivery of therapeutics across the blood brain barrier  which have been a bottleneck in treatment of various neurological disorders.
  • This presentation can be helpful in developing an robust brain delivery system and lead to international interdisciplinary collaborations for the treatment of various neurological disorders.


Mr. Sachin Kumar is Ph.D candidate at School of Medicine, Western Sydney University, Sydney  Australia . He is currently working in the Neuroimmunology laboratory headed by Associate Professor Mourad Tayebi on a Nano-carrier based brain-drug delivery system for the treatment of Alzheimer’s disease. Sachin is a biomedical engineer and received a Bachelor of Technology (B.Tech) and Master of Technology(M.Tech) in Biotechnology from Jaypee Institute of Information Technology (Deemed University) Noida,  India. His research interests are predominantly focused in developing novel drug delivery systems, nanoparticle formulations along with their characterization, efficacy and cytotoxicity evaluations.